493 related articles for article (PubMed ID: 26155041)
1. Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center.
Gupta V; Kumar A; Sharma P; Bansal N; Singla V; Arora A
J Clin Exp Hepatol; 2015 Jun; 5(2):134-41. PubMed ID: 26155041
[TBL] [Abstract][Full Text] [Related]
2. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
3. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India.
Gupta V; Kumar A; Sharma P; Tyagi P; Bansal N; Singla V; Arora A
J Clin Exp Hepatol; 2014 Dec; 4(4):287-92. PubMed ID: 25755575
[TBL] [Abstract][Full Text] [Related]
4. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.
Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G
Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
7. Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India.
Dixit VK; Ghosh JK; Lamtha SC; Kaushik P; Goyal SK; Behera MK; Singh N; Jain AK
J Clin Exp Hepatol; 2014 Jun; 4(2):101-5. PubMed ID: 25755547
[TBL] [Abstract][Full Text] [Related]
8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
9. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
Naik GS; Tyagi MG
J Clin Exp Hepatol; 2012 Mar; 2(1):42-54. PubMed ID: 25755405
[TBL] [Abstract][Full Text] [Related]
10. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
[TBL] [Abstract][Full Text] [Related]
11. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin.
Viganò M; Aghemo A; Iavarone M; Rumi MG; Agnelli F; Lampertico P; Donato MF; Colombo M
Antivir Ther; 2009; 14(6):789-96. PubMed ID: 19812441
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B Virus Infection can Cause Hepatocellular Carcinoma in Less Advanced Liver Cirrhosis: A Comparative Study of 142 Patients from North India.
Arora A; Sharma P; Tyagi P; Singla V; Arora V; Bansal N; Toshniwal J; Kumar A
J Clin Exp Hepatol; 2013 Dec; 3(4):288-95. PubMed ID: 25755516
[TBL] [Abstract][Full Text] [Related]
13. Consensus guidelines for the management of hepatitis C infection.
Consensus Guidelines Committee for the Management of Hepatitis C Infection
Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
[TBL] [Abstract][Full Text] [Related]
14. Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response.
Pinzone MR; Zanghì AM; Rapisarda L; D'Agata V; Benanti F; Spartà D; Nunnari G; Cacopardo B
Eur Rev Med Pharmacol Sci; 2014 Dec; 18(2 Suppl):11-5. PubMed ID: 25535185
[TBL] [Abstract][Full Text] [Related]
15. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
16. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.
Puri P; Anand AC; Saraswat VA; Acharya SK; Dhiman RK; Sarin SK; Singh SP; Chawla YK; Aggarwal R; Amarapurkar D; Arora A; Dixit VK; Sood A; Shah S; Duseja A; Kapoor D; Shalimar ; Madan K; Pande G; Nagral A; Kar P; Koshy A; Puri AS; Eapen CE; Thareja S
J Clin Exp Hepatol; 2015 Sep; 5(3):221-38. PubMed ID: 26628840
[TBL] [Abstract][Full Text] [Related]
17. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin in Combination with Pegylated Interferon and Ribavirin Provided High Rate of Sustained Virological Response in Patients with Genotype 3 Hepatitis C Virus.
Todorovska B; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Popova-Jovanovska R; Grivceva-Stardelova K; Licoska-Josifovic F; Andreevski V; Curakova-Ristovska E; Joksimovic N
Open Access Maced J Med Sci; 2019 May; 7(10):1641-1648. PubMed ID: 31210815
[TBL] [Abstract][Full Text] [Related]
19. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]